Anti-Human CD331/FGFR1 & KLB/Beta-klotho Bispecific Reference Antibody (Fazpilodemab, RUO)

Description: Fazpilodemab (BS10831) is a research-grade recombinant antibody targeting CD331. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 3.06mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: FLT2,HBGFR,BFGFR,FGFR-1,CEK,Fibroblastgrowthfactorreceptor1,FGFR1,bFGF-R-1,Fms-liketyrosinekinase2,FGFBR,FLT-2,CD331,Basicfibroblastgrowthfactorreceptor1,FLG,Proto-oncogenec-Fgr,N-sam,Klothobeta-likeprotein,KLB,Beta-klotho,BetaKlotho,BKL
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: Bispecific,BFKB8488A,CAS:2517935-02-1
Background: Fazpilodemab (BFKB8488A) is a humanized, agonistic, bispecific antibody targeting fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD).
Note: For research use only. Not suitable for clinical or therapeutic use.